Welcome to our dedicated page for Atreca news (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on Atreca stock.
Atreca Inc (NASDAQ: BCEL) is a clinical-stage biotechnology company advancing novel cancer immunotherapies through its proprietary Immune Repertoire Capture™ platform. This page provides investors and researchers with essential updates on corporate developments, preclinical advancements, and strategic partnerships.
Access timely updates on BCEL’s lead antibody-drug conjugate program APN-497444, financial restructuring efforts, and licensing agreements. Our curated news collection includes press releases about clinical milestones, executive leadership decisions, and collaborative research initiatives in oncology and infectious diseases.
Key content areas include updates on ADC therapeutic candidates, operational efficiency measures, partnership developments with global health organizations, and progress in leveraging Atreca’s discovery platform. All information is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to BCEL’s latest developments. For comprehensive understanding of Atreca’s innovative approach to immune-driven oncology therapies, check back regularly for new updates.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced it will present data from the Phase 1b study of ATRC-101 at the American Society of Clinical Oncology 2023 Annual Meeting from June 2-6 in Chicago. The presentation, titled "Interim update of the ATRC-101 phase 1b trial in advanced solid tumors", will take place on June 4, 2023, from 9:45 AM to 12:45 PM CDT. This trial aims to evaluate ATRC-101's effectiveness in treating multiple solid tumors, expanding Atreca's innovative antibody-based therapeutic portfolio that targets unique tumor antigens derived from the human immune response. The company is actively enrolling patients for this trial, highlighting its commitment to advancing cancer therapies.
Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, announced that CEO John A. Orwin will participate in a panel discussion on T-Cells and "Informative B-Cells" at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, from 10:00 to 10:45 AM ET. The panel aims to address innovative approaches in oncology. A live webcast will be available for registered attendees, who can also schedule one-on-one meetings with Atreca's management. The company's unique discovery platform focuses on developing novel therapeutics based on the human immune response, leading to candidates like ATRC-101, currently in a Phase 1b study for solid tumor cancers. For more details, visit Atreca's website.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), published its fourth quarter and full-year 2022 results, revealing a net loss of $97.2 million, translating to a net loss per share of $2.52. The ongoing Phase 1b trial for ATRC-101 shows promising results, with 59% disease control in patients with high target expression. The company expects go/no-go decisions for Phase 2 trials by year-end. Additionally, Atreca is advancing preclinical programs APN-497444 and APN-346958, with clinical candidate nominations anticipated in 2023. Financially, cash and equivalents stood at $70.5 million, with R&D expenses totaling $66.8 million for the year.
FAQ
What is the current stock price of Atreca (BCEL)?
What is the market cap of Atreca (BCEL)?
